| Literature DB >> 28903774 |
Rongjiong Zheng1,2, Yushan Mao3,4.
Abstract
BACKGROUND: Hypertension and the triglyceride and glucose index both have been associated with insulin resistance; however, the longitudinal association remains unclear. This study was designed to investigate the longitudinal association between the triglyceride and glucose index and incident hypertension among the Chinese population.Entities:
Keywords: Epidemiology; Hypertension; Triglyceride and glucose index
Mesh:
Substances:
Year: 2017 PMID: 28903774 PMCID: PMC5598027 DOI: 10.1186/s12944-017-0562-y
Source DB: PubMed Journal: Lipids Health Dis ISSN: 1476-511X Impact factor: 3.876
Baseline characteristics of the subjects according to TyG quartiles
| Variables | TyG quartile | ||||
|---|---|---|---|---|---|
| Quartile 1 ( | Quartile 2 ( | Quartile 3 ( | Quartile 4 ( |
| |
| TyG | 7.81 (7.65–7.97) | 8.21 (8.09–8.33) | 8.55 (8.42–8.68) | 9.04 (8.88–9.30) | < 0.001 |
| Gender (male/%) | 783/68.1 | 801/67.7 | 799/67.5 | 794/67.9 | 0.99 |
| Age (years) | 37.0 (32.0–44.0) | 39.0 (34.0–48.0) | 41.0 (35.0–51.0) | 45.0 (37.0–54.0) | < 0.001 |
| BMI (kg/m2) | 21.0 (19.6–22.9) | 21.9 (20.2–24.0) | 23.0 (21.2–24.7) | 23.9 (22.2–25.7) | < 0.001 |
| SBP (mmHg) | 113.0 (106.0–122.0) | 115.0 (107.0–124.0) | 119.0 (111.0–127.0) | 122.0 (114.0–128.0) | < 0.001 |
| DBP (mmHg) | 72.0 (67.0–78.0) | 74.0 (68.0–79.0) | 76.0 (70.0–81.0) | 78.0 (73.0–83.0) | < 0.001 |
| WC (cm) | 73.0 (68.0–79.0) | 76.0 (70.0–82.0) | 79.0 (72.0–85.0) | 82.0 (76.0–88.0) | < 0.001 |
| BUN (μmol/L) | 4.97 (4.24–5.75) | 4.93 (4.25–5.76) | 5.02 (4.18–5.82) | 4.97 (4.16–5.82) | 0.894 |
| Cr (μmol/L) | 72.0 (61.0–81.0) | 73.0 (62.0–81.0) | 73.0 (61.0–82.0) | 72.0 (61.0–81.0) | 0.849 |
| FPG (mmol/L) | 4.25 (3.99–4.51) | 4.39 (4.12–4.67) | 4.48 (4.20–4.81) | 4.67 (4.34–5.09) | < 0.001 |
| UA (μmol/L) | 305.0 (251.0–352.0) | 311.0 (253.0–367.0) | 333.0 (269.0–392.0) | 351.0 (286.0–402.0) | < 0.001 |
| AST (U/L) | 18.0 (16.0–22.0) | 19.0 (16.0–23.0) | 20.0 (17.0–24.0) | 21.0 (18.0–26.0) | < 0.001 |
| ALT (U/L) | 18.0 (14.0–25.0) | 20.0 (15.0–30.0) | 24.0 (17.0–36.0) | 28.0 (20.0–42.0) | < 0.001 |
| γ-GGT (U/L) | 14.0 (11.0–20.0) | 16.0 (12.0–23.0) | 19.0 (13.0–31.0) | 25.0 (16.0–41.0) | < 0.001 |
| TC (mmol/L) | 4.28 (3.78–4.80) | 4.58 (4.07–5.11) | 4.78 (4.21–5.35) | 5.12 (4.54–5.78) | < 0.001 |
| TG (mmol/L) | 0.73 (0.61–0.85) | 1.05 (0.90–1.20) | 1.44 (1.21–1.67) | 2.28 (1.87–2.92) | < 0.001 |
| HDL-C (mmol/L) | 1.36 (1.11–1.67) | 1.29 (1.08–1.59) | 1.22 (1.05–1.50) | 1.22 (1.071.45) | < 0.001 |
| LDL-C (mmol/L) | 2.27 (1.90–2.68) | 2.56 (2.10–3.05) | 2.73 (2.26–3.26) | 2.89 (2.39–3.46) | < 0.001 |
| Apo-A1(g/L) | 1.33 (1.17–1.49) | 1.31 (1.14–1.49) | 1.28 (1.11–1.49) | 1.27 (1.10–1.47) | 0.228 |
| Apo-B(g/L) | 0.77 (0.64–0.90) | 0.86 (0.73–1.00) | 0.95 (0.81–1.10) | 1.06 (0.89–1.23) | < 0.001 |
| eGFR (mL/(min·1.73 m2)) | 112.2 (99.8–127.1) | 109.9 (99.1–123.4) | 109.0 (97.1–123.7) | 108.9 (96.3–123.5) | < 0.001 |
Fig. 1The association between the baseline TyG index and the cumulative incidence of HTN
Baseline characteristics of the subjects according to follow-up outcomes
| Variables | Subjects developed HTN ( | Subjects did not develop HTN ( |
|
|---|---|---|---|
| TyG | 8.55 (8.20–8.92) | 8.23 (7.92–8.59) | < 0.001 |
| Gender (male/female, n) | 1541/506 | 1636/1003 | < 0.001 |
| Age (years) | 44.0 (36.0–54.0) | 38.0 (33.0–46.0) | < 0.001 |
| BMI (kg/m2) | 23.6 (21.8–25.4) | 21.7 (19.8–23.6) | < 0.001 |
| SBP (mmHg) | 124.0 (117.0–131.0) | 112.0 (105.0–120.0) | < 0.001 |
| DBP (mmHg) | 80.0 (75.0–84.0) | 71.0 (67.0–76.0) | < 0.001 |
| WC (cm) | 81.0 (75.0–87.0) | 75.0 (69.0–81.0) | < 0.001 |
| BUN (μmol/L) | 5.09 (4.29–5.96) | 4.86 (4.15–5.66) | < 0.001 |
| Cr (μmol/L) | 74.0 (64.0–83.0) | 71.0 (60.0–80.0) | < 0.001 |
| FPG (mmol/L) | 4.53 (4.21–4.89) | 4.37 (4.09–4.66) | < 0.001 |
| UA (μmol/L) | 342.0 (284.0–395.0) | 306.0 (250.0–364.0) | < 0.001 |
| AST (U/L) | 20.0 (17.0–25.0) | 19.0 (16.0–23.0) | < 0.001 |
| ALT (U/L) | 25.0 (17.0–37.0) | 20.0 (15.0–30.0) | < 0.001 |
| γ-GGT (U/L) | 21.0 (15.0–34.0) | 16.0 (11.0–24.0) | < 0.001 |
| TC (mmol/L) | 4.83 (4.28–5.50) | 4.56 (3.99–5.14) | < 0.001 |
| TG (mmol/L) | 1.38 (1.01–2.02) | 1.07 (0.80–1.51) | < 0.001 |
| HDL-C (mmol/L) | 1.26 (1.07–1.52) | 1.27 (1.08–1.58) | 0.020 |
| LDL-C (mmol/L) | 2.73 (2.24–3.29) | 2.51 (2.04–3.03) | < 0.001 |
| Apo-A1 (g/L) | 1.29 (1.13–1.50) | 1.30 (1.13–1.48) | 0.815 |
| Apo-B (g/L) | 0.97 (0.81–1.14) | 0.85 (0.71–1.01) | < 0.001 |
| eGFR (mL/(min·1.73 m2)) | 108.0 (95.0–122.0) | 111.6 (100.2–126.2) | < 0.001 |
Univariate and multivariate Cox Proportional Hazard models of development of HTN during 9-year follow-up
| Variables | Univariate models | Multivariate models | ||
|---|---|---|---|---|
| HR (95%CI) |
| HR (95%CI) |
| |
| Gender (male) | 1.62 (1.46–1.78) | < 0.001 | 1.33 (1.14–1.56) | < 0.001 |
| Age (years) | 1.03 (1.03–1.04) | < 0.001 | 1.03 (1.02–1.03) | < 0.001 |
| BMI (kg/m2) | 1.16 (1.15–1.18) | < 0.001 | 1.09 (1.06–1.12) | < 0.001 |
| WC (cm) | 1.06 (1.05–1.06) | < 0.001 | 1.01 (1.00–1.02) | 0.017 |
| BUN (mmol/L) | 1.11 (1.07–1.15) | < 0.001 | 1.00 (0.96–1.04) | 0.967 |
| Cr (μmol/L) | 1.00 (1.00–1.01) | < 0.001 | 1.00 (1.00–1.01) | 0.018 |
| FPG (mmol/L) | 1.26 (1.21–1.30) | < 0.001 | 1.10 (1.03–1.18) | 0.006 |
| UA (μmol/L) | 1.01 (1.00–1.00) | < 0.001 | 1.00 (1.00–1.00) | 0.006 |
| AST (U/L) | 1.01 (1.00–1.01) | < 0.001 | 1.00 (1.00–1.01) | 0.648 |
| ALT (U/L) | 1.00 (1.00–1.00) | < 0.001 | 1.00 (1.00–1.00) | 0.433 |
| γ-GGT (U/L) | 1.00 (1.00–1.01) | < 0.001 | 1.00 (1.00–1.00) | 0.001 |
| TC (mmol/L) | 1.28 (1.22–1.34) | < 0.001 | 1.16 (0.95–1.43) | 0.144 |
| TG (mmol/L) | 1.29 (1.25–1.33) | < 0.001 | 1.08 (0.94–1.24) | 0.264 |
| HDL-C (mmol/L) | 0.86 (0.77–0.97) | 0.010 | 0.96 (0.74–1.25) | 0.756 |
| LDL-C (mmol/L) | 1.31 (1.24–1.38) | < 0.001 | 0.84 (0.70–1.02) | 0.073 |
| Apo-A1 (g/L) | 1.02 (0.86–1.21) | 0.812 | 1.07 (0.86–1.33) | 0.562 |
| Apo-B (g/L) | 3.47 (2.95–4.09) | < 0.001 | 1.15 (0.78–1.70) | 0.490 |
| eGFR (mL/(min·1.73 m2)) | 1.00 (0.99–1.00) | < 0.001 | 1.00 (1.00–1.00) | 0.238 |
| TyG | < 0.001 | 0.013 | ||
| Quartile 1 | 1.00 (reference) | 1.00 (reference) | ||
| Quartile 2 | 1.38 (1.20–1.59) | 1.21 (1.00–1.47) | ||
| Quartile 3 | 2.00 (1.74–2.29) | 1.49 (1.16–1.93) | ||
| Quartile 4 | 2.63 (2.31–3.00) | 1.53 (1.07–2.19) | ||
Risk of development HTN according to baseline TyG categories in unadjusted and adjusted models
| Models | Quartile 1 (n = 1149) | Quartile 2 (n = 1183) | Quartile 3 (n = 1184) | Quartile 4 (n = 1170) |
|
|---|---|---|---|---|---|
| Unadjusted | 1.00 (reference) | 1.38 (1.20–1.59) | 2.00 (1.74–2.29) | 2.63 (2.31–3.00) | < 0.001 |
| Mode 1 (Adjusted for age and gender) | 1.00 (reference) | 1.32 (1.14–1.52) | 1.79 (1.56–2.05) | 2.21 (1.94–2.53) | < 0.001 |
| Mode 2 (Adjusted for age, gender, and BMI) | 1.00 (reference) | 1.19 (1.03–1.38) | 1.51 (1.32–1.74) | 1.71 (1.48–1.96) | < 0.001 |
| Mode 3 (Adjusted for age gender and all clinical variablesa) | 1.00 (reference) | 1.21 (1.00–1.47) | 1.49 (1.16–1.93) | 1.53 (1.07–2.19) | 0.013 |
aIncluding BMI, WC, BUN, Cr, FPG, UA, AST, ALT, γ-GGT, TC, TG, HDL-C, LDL-C, Apo-A1, Apo-B, and eGFR